Navigation Links
Harrisvaccines Awarded National Institute of Food and Agriculture Grant for Swine Disease Research

AMES, Iowa, Oct. 1, 2013 /PRNewswire/ -- Ames, Iowa-based vaccine producer, Harrisvaccines, today announced it has been awarded a grant from the USDA National Institute of Food and Agriculture (NIFA) for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) research. This project is supported by Agriculture and Food Research Initiative Grant no. 2013-67015-21307 from the USDA National Institute of Food and Agriculture.

The grant, titled Proteomics-defined Porcine Reproductive and Respiratory Syndrome Virus Immunoproteome, will be a two-year project, beginning on October 1, 2013. Dr. Mark Mogler, Head of Research for Harrisvaccines, and Dr. Kurt Kamrud collaborated in achieving the grant with Dr. Manohar John of PathoVacs. Dr. Mogler will be serving as Project Director.

The basic research project will focus on a new way of looking for protective determinants of the PRRS virus. Harrisvaccines will be generating protein fragment libraries of PRRSV strains and the PRRSV protein fragment libraries will be screened using innovative technology developed by their collaborator on the project, Dr. John.

"Dr. John has a novel technology that allows him to screen thousands of antigens at a time," said Dr. Mogler. "This will be very beneficial, because rather than looking at only one antigen at a time, we will be able to look at tens of thousands simultaneously."

During the first year of the project, Harrisvaccines will be generating the fragments and creating fragment libraries for screening; screening will also be done during the first year. The second year of the project will mainly consist of data analysis and confirmatory testing.

At the end of the two years, Dr. Mogler is confident that Harrisvaccines will be able to characterize the immune response to PRRSV proteins by identifying reactive sites that otherwise, would not have been found.

"Ideally we would find a sequence, or a set of sequences, that are found across all PRRSV strains. We could then use these to make a more effective PRRSV vaccine," Dr. Mogler explained.

About Harrisvaccines

Headquartered in Ames, Iowa, Harrisvaccines focuses on revolutionizing animal health vaccines and enhancing productivity in the swine, cattle, equine, and farmed aquaculture industries. Using state-of-the-art advanced molecular science, Harrisvaccines employs their unique SirraVax(SM) RNA Particle (RP) technology platform to develop rapid-response, herd-specific products for animal diseases. To learn more about Harrisvaccines, visit

About PathoVacs

PathoVacs Incorporated is an early stage Biotechnology Company based in Ames, IA. The Company is based on a highly innovative proteome mining platform for novel protein antigen discovery for development of broadly protective/universal subunit vaccines against infectious agents that cause diseases in humans, livestock and poultry.  

SOURCE Harrisvaccines
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Lpath Awarded NIH SBIR Grant for Lpathomab
2. Rudolf Kingslake Medal Awarded by SPIE for TNO Paper on Color Image Fusion for Night-Vision Applications
3. Genia Technologies, Columbia University, and Harvard University Awarded $5.25 Million Grant from NIH to Accelerate the Development of NanoTag DNA Sequencing Technology
4. Rhythm Awarded $1.35 Million from The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinsons Disease
5. VolitionRx-led Consortium Awarded euro 780 000 ($1M approx.) Eurostars Grant
6. Fumio Hirakawa has been awarded with the notable Golden A' Design Award
7. Curemark Awarded New Patent For Treatment Of Drug And Alcohol Addiction
8. VG Energy Chief Scientist Awarded $200,000 AgriLife Grant to Study Lipid Secretion
9. Boehringer Laboratories LLC Awarded HPG Contract for Clinical Suction Regulators
10. ConfometRx Awarded Patent on GPCRs that Contain a Stabilizing IC2 Fusion Protein
11. Puritan Awarded New Canadian Patent for PurFlock® Ultra Flocked Swab
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... -- Studies reveal the differences in species ... the way for more effective treatment for one of the ... --> --> Gum disease ... cats, yet relatively little was understood about the bacteria associated ... conducted by researchers from the WALTHAM Centre for Pet Nutrition ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):